KR100831092B1 - Skin whitening composition containing celastrus orbiculatus extract - Google Patents
Skin whitening composition containing celastrus orbiculatus extract Download PDFInfo
- Publication number
- KR100831092B1 KR100831092B1 KR1020060120894A KR20060120894A KR100831092B1 KR 100831092 B1 KR100831092 B1 KR 100831092B1 KR 1020060120894 A KR1020060120894 A KR 1020060120894A KR 20060120894 A KR20060120894 A KR 20060120894A KR 100831092 B1 KR100831092 B1 KR 100831092B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- novak
- skin whitening
- composition
- celastrus orbiculatus
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
도 1은 노박덩굴 추출물에 의한 티로시네이즈의 단밸질 발현 억제 효과를 웨스턴 블럿(Western blot)으로 분석한 결과이다.1 is a result of Western blot analysis of the inhibitory effect of tyrosinase on the expression of tyrosinase by Novak extract.
본 발명은 노박덩굴 추출물을 함유하는 피부 미백 조성물에 관한 것으로서, 더욱 상세하게는 노박덩굴(Celastrus orbiculatus ) 추출물이 티로시네이즈 발현 억제활성, 멜라닌 생합성 저해 활성이 우수함을 확인함으로써 노박덩굴 추출물을 유효성분으로 함유하는 피부 미백용 조성물에 관한 것이다. The present invention relates to a skin whitening composition containing Novak vine extract, and more particularly, Novak vine ( Celastrus vine) Orbiculatus ) relates to a composition for skin whitening containing Novak vine extract as an active ingredient by confirming that the extract is excellent in tyrosinase expression inhibitory activity, melanin biosynthesis inhibitory activity.
멜라닌은 색소 세포 내에 존재하는 티로시네이즈 작용에 의해 타이로신으로부터 도파(dopa), 도파퀴논(dopaquinone)으로 변환되어 도파크롬(dopachrome) 등을 거쳐 생성되어 진다. 이 멜라닌은 피부에 존재하여 자외선 등으로부터 신체를 보호하는 중요한 기능을 가지고 있다. 그러나 멜라닌이 과잉 생산됨으로써 기 미, 주근깨 등을 형성하고, 피부노화를 촉진하며, 피부암 유발에 중요한 작용을 하는 것으로 알려져, 최근에는 멜라닌 과잉생성을 예방하는 약제개발이 활발히 진행되고 있다. 이미 미백효과제로서는 파라-메톡시페놀(p-methoxyphenol), 하이드로퀴논(hydroquinone), 코지산(kojic acid), 알부틴(arbutin) 등이 사용되고 있으나, 이들은 활성이 약하거나 색소세포의 변성 또는 치사를 일으키거나 세포 본래의 기능을 손상시키는 등 부작용이 있는 경우도 있다. 한편, 멜라닌 생성 억제를 목적으로 비타민 C 및 그 유도체 등이 사용되고 있으나, 이들 또한 저해활성이 낮다는 단점을 가지고 있다. 따라서 소량으로도 멜라닌 생합성 저해활성을 나타내는 물질의 개발이 요구된다.Melanin is converted from tyrosine to dopa and dopaquinone by tyrosinase action present in pigment cells, and is produced via dopachrome and the like. This melanin is present in the skin and has an important function of protecting the body from ultraviolet rays. However, over-production of melanin is known to play an important role in forming blemishes, freckles, etc., promoting skin aging, and inducing skin cancer, and in recent years, the development of drugs for preventing melanin overproduction is actively underway. Para-methoxyphenol, hydroquinone, kojic acid, arbutin and the like are already used as whitening agents, but they are weak in activity or denature or kill pigment cells. There are also side effects, such as causing or impairing the cell's original function. On the other hand, vitamin C and derivatives thereof are used for the purpose of inhibiting melanin production, but they also have the disadvantage of low inhibitory activity. Therefore, the development of a substance that exhibits melanin biosynthesis inhibitory activity in a small amount is required.
노박덩굴(Celastrus orbiculatus Thunb)은 잎지며 덩굴뻗는 떨기나무이다. 줄기는 길이 12 m에 이르며 타원형의 잎이 어긋나게 붙는다. 봄철에 노란풀색의 작은꽃이 핀다. 각지의 산기슭, 낮은산, 돌각담 등에서 자란다. 뿌리와 잎, 열매에 알카로이드, 잎에 0.3%의 플라보노이드인 켐페리트린, 켐페롤-3,7-디람노시드, 켐페롤-3-P-쿠마로일글루코시드가 있다. 동의치료에서 뿌리를 피순환을 잘되게 하는 약으로 쓴다. 민간에서는 씨 1 ∼ 1.5개를 허리아픔, 류마티스에 먹으면 진경 진통작용이 있다고 한다. 또한, 노박덩굴속 식물의 씨는 월경이 없을 때 쓰면 성기능을 높이는 약, 염증약, 항종양약, 방부약, 열물내기약으로 쓴다. 뿌리껍질은 마취약, 오줌내기 약, 땀내기 약, 류산시키는 약, 설사약, 살충약으로 쓴다. 잎즙은 아편 중독 때 독풀이약으로 쓴다. 나무껍질을 섬유원료로 쓴다. 상기와 같이 노박덩굴은 여러 방면에서 특유의 치료 효능을 나타 내는 것으로 구전되어 왔으나 과학적으로 검증된 바 없다. 특히, 노박덩굴의 피부 미백 효과에 대해서는 과학적인 검증은 물론 민간요법에서 조차도 알려진 바 없다.The celticus ( Celastrus orbiculatus Thunb) is a leafy, vine-growing bush. The stem reaches 12 m long and the oval leaves are alternately attached. Yellow full-colored small flowers bloom in spring. It grows in the foothills, low mountains, and stone carving walls of various places. There are alkaloids in the roots, leaves and fruits, and 0.3% flavonoids in the leaves, camperitririn, camphorol-3,7-diramnoside, and camphorol-3-P-coumaroylglucoside. In motion therapy, roots are used as medicines to improve circulation. In the private sector, 1 to 1.5 seeds to eat back pain, rheumatism is said to have analgesic pain. In addition, the seeds of the genus Nova are used as drugs to increase sexual function, inflammation drugs, anti-tumor drugs, preservatives, fever-fed medicines when there is no menstruation. Root bark is used as anesthetic, urinating, sweating, acidifying, diarrhea and insecticide. Leaf juice is used as poison poison when opium poisoning. Bark is used as a fiber material. As mentioned above, Novak vines have been shown to exhibit unique therapeutic efficacy in many aspects, but have not been scientifically verified. In particular, the skin whitening effects of vines are not known even in folk medicine as well as scientific verification.
이에, 본 발명자들은 천연물질로부터 미백효과가 우수한 물질을 탐색하던 중, 안전성이 이미 확보된 생약 및 식물을 추출하여 미백의 효능을 검색한 결과 노박덩굴이 멜라닌 생성 저해 효과를 가진다는 것을 밝힘으로써 본 발명을 완성하게 되었다. Therefore, the present inventors searched for substances with excellent whitening effect from natural substances, and found that the vines have a melanin inhibitory effect as a result of searching for the efficacy of whitening by extracting herbs and plants which have already been secured with safety. The invention was completed.
따라서, 본 발명은 노박덩굴 추출물을 유효성분으로 함유하는 피부 미백용 조성물을 제공하는 데 그 목적으로 한다. Therefore, an object of the present invention is to provide a composition for skin whitening containing Novak extract as an active ingredient.
본 발명은 노박덩굴 추출물을 유효성분으로 함유하는 피부 미백용 조성물을 그 특징으로 한다.The present invention is characterized by a composition for skin whitening containing Novak extract as an active ingredient.
이와 같은 본 발명을 더욱 상세하게 설명하면 다음과 같다.The present invention will be described in more detail as follows.
본 발명은 노박덩굴(Celastrus orbiculatus) 추출물이 티로시네이즈 발현 억제활성, 멜라닌 생합성 저해 활성이 우수함을 확인함으로써 노박덩굴 추출물을 유효성분으로 함유하는 피부 미백용 조성물에 관한 것이다. The present invention relates to a composition for skin whitening containing Novak vine extract as an active ingredient by confirming that the extract of Nova celica ( Celastrus orbiculatus) is excellent in inhibiting tyrosinase expression and inhibiting melanin biosynthesis.
노박덩굴로부터 노박덩굴 추출물을 얻는 과정을 설명하면 다음과 같다. Referring to the process of obtaining the extract of Novak from Novak vine is as follows.
먼저, 자생 또는 재배한 노박덩굴을 채취하여 쇄절한다. 그리고, 저급 알콜로 24 ~ 48 시간 환류 추출하고 감압 여과한 후, 그 여액을 20 ~ 50 ℃에서 감압 농축하여 분말로 얻는다. 상기 저급 알콜은 탄소수 1 ~ 6의 알코올로서, 더욱 바람직하게는 메탄올, 에탄올, 부탄올 용매 등이다. First, the native vines are grown and cultivated. The mixture was extracted under reflux with a lower alcohol for 24 to 48 hours, filtered under reduced pressure, and the filtrate was concentrated under reduced pressure at 20 to 50 ° C to obtain a powder. The lower alcohol is an alcohol having 1 to 6 carbon atoms, more preferably methanol, ethanol, butanol solvent or the like.
상기한 추출물의 활성의 추적은 멜란-에이 세포(melan-a cell)의 멜라닌 생성율에 기준을 두어 다음과 같은 방법으로 측정하였다. Tracking of the activity of the extract was measured based on the melanin production rate of melan-A cells in the following method.
멜란-에이 세포(melan-a cell)를 10% 혈청(Fetal Bovine Serum)이 첨가된 알피엠아이 1640(RPMI 1640) 배지에 페니실린-스트렙토마이신(penicillin-streptomycin) 100 ㎍/㎖를 첨가하고 사용하기 직전에 200 nM 티피에이(TPA, tetradeconyl phorbol acetate)를 첨가하여 배양한 후, 24 웰(well)에 1 × 105 cells/㎖로 분주한 뒤 24시간 후, 검체를 농도별로 3일을 처리한 후, 하루 더 배양하고 생성된 멜라닌 양을 대조구를 100%로 놓고 비교하여 판별하였다. Melan-a cells were added to 100 μg / ml of penicillin-streptomycin in RPMI 1640 medium to which 10% serum (Fetal Bovine Serum) was added. After incubating with 200 nM TPE (TPA, tetradeconyl phorbol acetate), the cells were dispensed at 1 × 10 5 cells / ml in 24 wells, and after 24 hours, the samples were treated for 3 days by concentration. , And cultured for one more day and the amount of melanin produced was determined by comparing the control with 100%.
그 결과, 노박덩굴 추출물이 공지의 미백성분인 코지산에 비해 멜라닌 생합성 저해 활성이 현저히 우수함을 밝히고 있다.As a result, it is revealed that the extract of Novak vine is significantly superior in inhibiting melanin biosynthesis activity compared to kojic acid, which is a known whitening component.
또한, 노박덩굴 추출물의 티로시네이즈의 발현 억제 효과 역시 우수하게 나타나는 바, 본원발명은 노박덩굴 추출물이 유효성분으로 함유된 피부 미백 조성물을 그 특징이 있다.In addition, bark vine extract bark tyrosinase expression inhibitory effect is also excellent bar, the present invention is characterized by the skin whitening composition containing the vine extract as an active ingredient.
본 발명에 따른 조성물은 의약품으로서 직접 사용하거나 또는 화장품, 식품 등에 함유되어 피부질환치료 및 피부 미백효과를 발현 또는 식품의 갈변을 방지하 게 된다. The composition according to the present invention is used directly as a medicine or contained in cosmetics, foods, etc. to prevent skin disease and the skin whitening effect or to prevent browning of food.
상기 노박덩굴 추출물을 유효성분으로 포함하는 조성물은 임상 투여 시에 경구 또는 비경구로 투여할 수 있으며, 일반적인 의약품, 의약외품 및 기능성 식품 등의 형태로 사용될 수 있다.The composition comprising the Novak extract as an active ingredient may be administered orally or parenterally during clinical administration, and may be used in the form of general medicines, quasi-drugs, and functional foods.
본 발명의 조성물을 의약품으로 사용하는 경우, 노박덩굴 추출물을 임상적으로 이용 시에는 약학적 분야에서 통상적인 담체와 함께 배합하여 약학적 분야에서 통상적인 제제, 예를 들면 정제, 캅셀제, 트로키제, 액제, 현탁제 등의 경구투여용 제제; 주사용 용액 또는 현탁액, 또는 주사시에 주사용 증류수로 제조하여 사용할 수 있는 즉시 사용형 주사용 건조분말 등의 형태인 주사용 제제; 또는 연고제 등의 다양한 제제로 제형화할 수 있다. 통상적인 담체를 상용하여 제조된 약학적 제제는 경구적으로 투여하거나, 비경구적으로 예를 들면 정맥내, 피하, 복강내 또는 국소 적용할 수 있다. 본 발명의 노박덩굴 추출물의 투여량은 환자의 나이, 상태 등에 따라 차이가 있으나, 일반적으로 성인에게 1일에 10 ~ 500 mg, 바람직하게는 50 ~ 300 mg의 양이 투여되도록 하며, 의사 또는 약사의 판단에 따라 일정시간 간격으로 1일 수회, 바람직하기로는 1회 내지는 6회 분할 투여할 수 있다.When the composition of the present invention is used as a medicament, when the Nova vine extract is used clinically, it is combined with a conventional carrier in the pharmaceutical field to prepare a conventional agent in the pharmaceutical field, such as tablets, capsules, troches, Preparations for oral administration such as solutions and suspensions; Injectable preparations in the form of injectable solutions or suspensions, or ready-to-use injectable dry powders which can be prepared and used as injectable distilled water upon injection; Or in various preparations such as ointments. Pharmaceutical formulations prepared using conventional carriers can be administered orally or parenterally, for example, intravenously, subcutaneously, intraperitoneally or topically. The dose of Novak extract of the present invention varies depending on the age, condition, etc. of the patient, but in general, 10 to 500 mg, preferably 50 to 300 mg per day is administered to an adult, doctor or pharmacist Depending on the judgment can be divided into several times a day, preferably once or six times a predetermined time interval.
또한, 본 발명의 조성물을 화장품으로 사용하는 경우, 노박덩굴 추출물을 기초제품 화장료(화장수, 크림, 에센스, 클렌징 폼, 클렌징 워터, 팩), 바디제품 화장료(바디 로션, 바디 오일, 바디 젤), 색조제품 화장료(화운데이션, 립스틱, 마스카라, 메이크업 베이스), 두발제품 화장료(샴푸, 린스, 헤어 콘디셔너, 헤어 젤), 등에 화장료의 건조중량에 대하여 0.05 ~ 10.0 중량%의 함량으로 배합하여 사용할 수 있다. In addition, when the composition of the present invention is used as a cosmetic, Novak vine extract is a basic product cosmetics (cosmetics, creams, essences, cleansing foam, cleansing water, pack), body cosmetics (body lotion, body oil, body gel), It can be used in combination with a cosmetic product (foundation, lipstick, mascara, makeup base), hair cosmetics (shampoo, rinse, hair conditioner, hair gel), etc. in an amount of 0.05 to 10.0% by weight based on the dry weight of the cosmetic.
또한, 본 발명의 노박덩굴 추출물을 각종 식품의 건조중량에 대하여 0.05 ~ 10.0 중량% 함량으로 배합하여 미백효과를 가지는 식품을 제조할 수도 있다.In addition, it is also possible to prepare a food having a whitening effect by combining the Novak extract of the present invention in a content of 0.05 to 10.0% by weight based on the dry weight of various foods.
또한, 여기에서, 기능성 식품으로서는 과자, 가공식품, 조합 유지, 유제품, 음료 등의 각종 식품을 들 수 있고, 형상ㆍ성상도 특별히 제한되지 않아 고체 형상, 반고체 형상, 겔 형상, 액체 형상, 분말 형상 등 어느 것이라도 된다. Here, the functional food includes various foods such as confectionery, processed food, combination fat, dairy products, beverages, and the like. The shape and properties are not particularly limited, and the solid, semi-solid, gel, liquid, and powder forms Etc. may be sufficient.
즉, 본 발명의 조성물을 섭취함으로써 그 미백 효과를 발현하는 것으로, 거뭇한 피부나 기미, 주근깨, 다크서클을 개선 혹은 방지하여, 투명감 있는 아름다운 피부로 유지하는데 크게 기여할 수 있다.That is, by ingesting the composition of the present invention to express the whitening effect, it can greatly contribute to improve or prevent dark skin, blemishes, freckles, dark circles to maintain a beautiful skin with a sense of transparency.
이하, 실시예를 들어 본 발명을 상세히 기술할 것이나 본 발명의 범위를 이들 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited to these Examples.
실시예Example 1: 노박덩굴 추출물의 제조 1: Preparation of Novage Extract
제주도에서 채취한 노박덩굴 3 kg을 2 ㎝ 크기로 절단하고 80% 메탄올 수용액으로 48 시간 동안 환류 추출하여 감압여과한 후 그 여액을 40 ℃의 수조에서 감압 농축하여 농축된 메탄올 농축액을 얻었다. 농축 후 얻어진 엑기스는 동결 건조시켜 분말 상태의 노박덩굴 추출물을 얻었다.3 kg of Novak vines collected from Jeju Island were cut to 2 cm in size, extracted under reflux with an aqueous 80% methanol solution for 48 hours, filtered under reduced pressure, and the filtrate was concentrated under reduced pressure in a 40 ° C water bath to obtain a concentrated methanol concentrate. The extract obtained after concentration was lyophilized to obtain a powdery extract of Novak.
실시예 2: 멜라닌 생성 저해효과 측정Example 2: measurement of melanin production inhibitory effect
상기 실시예 1에서 얻은 노박덩굴 추출물과 시료를 첨가하지 않은 대조군과 코지산을 첨가한 양성대조군의 세포의 멜라닌 함량과 비교하여 멜라닌 생성 저해정도를 측정하는 방법인 둘레이 등[Dooley T. P. et al., Skin Pharmacol. 1994 7 188]의 방법에 의하여 멜라닌 생합성 억제율을 측정하였고, 그 결과를 다음 표 1에 나타내었다. Compared to the melanin content of the cells of the control group without addition of the control extract and the kojic acid obtained in Example 1 and the positive control group added koji acid, the circumference is a method of measuring the melanin production inhibition [Dooley TP et al., Skin Pharmacol. 1994 7 188] melanin biosynthesis inhibition rate was measured by the method, the results are shown in Table 1 below.
상기 표 1에 따르면, 본 발명의 노박덩굴 추출물은 기존의 미백성분으로 알려진 코지산에 비해 4배나 뛰어난 멜라닌 생합성 억제율을 나타내는 것을 확인할 수 있었다.According to Table 1, it was confirmed that the Novak extract of the present invention showed melanin biosynthesis inhibition rate four times higher than Koji acid known as a conventional whitening component.
실시예 3: 노박덩굴 추출물의 티로시네이즈 발현 억제 효과 확인Example 3: Confirmation of tyrosinase expression inhibitory effect of the extract
본 발명은 노박덩굴 추출물이 티로시네이즈의 발현 억제효과를 웨스턴 블럿(Western blot) 분석을 통하여 확인하기 위하여 다음과 같이 실험하였다. The present invention was tested as follows in order to confirm the inhibition effect of tyrosinase expression by Novak vine extract through Western blot analysis.
멜란-에이 세포(melan-a cell)를 10% 혈청(Fetal Bovine Serum)이 첨가된 알피엠아이 1640(RPMI 1640) 배지에 페니실린-스트렙토마이신(penicillin-streptomycin) 100 ㎍/㎖를 첨가하고 사용하기 직전에 200 nM 티피에이(TPA, tetradeconyl phorbol acetate)를 첨가하여 배양한 후, 1 × 105 cells/㎖로 분주한 뒤, 노박덩굴 추출물을 40, 20, 10, 5.0, 2.5 ㎍/㎖ 농도로 처리하여 37 ℃, 5% CO2에서 농도별로 3일을 처리한 후, 하루 더 배양하였다. 배양된 세포로부터 단백질 추출 완충용액을 이용하여 세포 분해 산물(total cell lysates)을 제조하여[N. Suh et al, Cancer Res., 1998, 58, 712-723], 단백질 발현 양상을 웨스턴 블럿 분석하였다.Melan-a cells were added to 100 μg / ml of penicillin-streptomycin in RPMI 1640 medium to which 10% serum (Fetal Bovine Serum) was added. Incubated with 200 nM TPE (TPA, tetradeconyl phorbol acetate), incubated at 1 x 10 5 cells / ml, and treated with 40, 20, 10, 5.0, 2.5 ㎍ / ml At 37 ° C., 5% CO 2 After three days of treatment for each concentration, the culture was further one day. The total cell lysates were prepared using protein extraction buffer from the cultured cells [N. Suh et al, Cancer Res., 1998, 58, 712-723], were analyzed by Western blot.
도 1은 노박덩굴 추출물의 티로시네이즈 발현 억제 효과를 웨스턴 블럿(Western blot)으로 분석한 결과로서, 노박덩굴 추출물을 처리 시 티로시네이즈 단백질 발현이 억제되었다. 1 is a result of Western blot analysis of tyrosinase expression inhibitory effect of Novak extract, the tyrosinase protein expression was inhibited when the Novak extract was treated.
실시예Example 4: 독성실험 4: Toxicity test
실시예 1의 노박덩굴 추출물에 대한 독성을 알아보기 위하여, 추출물 1 ~ 20 ㎎을 24 마리의 생쥐에게 복강 내 투여하여 행동 관찰 후 24시간 생존 여부를 확인하였다. 그 결과 20 ㎎을 투여한 6 마리 중 3 마리가 생존하고 나머지 3 마리는 희생당하였음을 알 수 있었다. 반면에, 20 ㎎ 미만의 용량을 투여한 생쥐의 경우는 모두 생존하였으며, 행동 관찰상 약물을 투여하지 않았던 생쥐와 비교하여 통계학상의 유의성 있는 차이를 보이지 않았다. 이상의 결과를 고려할 때, 생쥐에서 추출물의 대략적인 반수가 생존할 독성 용량(TD50)은 20 mg(1 mg/g)으로 판단된다.In order to determine the toxicity of the Novak extract of Example 1, the extract 1 ~ 20 mg was administered intraperitoneally to 24 mice to confirm the survival for 24 hours after behavior observation. As a result, it was found that 3 out of 6 mice administered 20 mg survived and the remaining 3 were sacrificed. On the other hand, all mice that received the dose of less than 20 mg survived, and showed no statistically significant difference compared to the mice that did not receive the drug in behavioral observation. Considering the above results, a toxic dose (TD 50 ) in which approximately half of the extracts survive in mice is judged to be 20 mg (1 mg / g).
제조예Production Example 1: 정제의 제조 1: Preparation of Tablet
본 발명의 노박덩굴 추출물을 이용하여 다음과 같은 조성으로 경구 투여용 정제를 습식과립법 및 건식과립법을 이용하여 제조하였다.Using the Novak extract of the present invention, a tablet for oral administration was prepared by using a wet granulation method and a dry granulation method with the following composition.
[조성][Furtherance]
노박덩굴 추출물 200 mg, 경질 무수규산 10 mg, 스테아린산 마그네슘 2 mg, 미세결정 셀룰로오즈 50 mg, 전분 글리콜산 나트륨 25 mg, 옥수수 전분 113 mg, 무수에탄올 적량.200 mg of Novak extract, 10 mg of hard silicic anhydride, 2 mg of magnesium stearate, 50 mg of microcrystalline cellulose, 25 mg of sodium starch glycolate, 113 mg of corn starch, proper amount of ethanol anhydride.
제조예Production Example 2: 연고제의 제조 2: Preparation of Ointment
본 발명의 노박덩굴 추출물을 이용하여 다음과 같은 조성으로 연고제를 제조하였다.Using oak extract of the present invention was prepared an ointment with the following composition.
[조성][Furtherance]
노박덩굴 추출물 5 g, 세틸팔미테이트 20 g, 세탄올 40 g, 미리스탄이소프로필 80 g, 모노스테아린산소르비탄 20 g, 폴리솔베이트 60 g, 파라옥시안식향산 프로필 1 g, 파라옥시안식향산 메틸 1 g, 인산 및 정제수 적량.5 g of Novak extract, cetyl palmitate 20 g, cetanol 40 g, myristan isopropyl 80 g, monostearate sorbitan 20 g, polysorbate 60 g, paraoxybenzoic acid propyl 1 g, paraoxybenzoic acid methyl 1 g , Phosphoric acid and purified water quantities.
제조예Production Example 3: 주사제의 제조 3: Preparation of Injection
본 발명의 노박덩굴 추출물을 이용하여 다음과 같은 조성으로 주사제를 제조하였다.Using the Novak extract of the present invention was prepared an injection with the following composition.
[조성][Furtherance]
노박덩굴 추출물 100 mg, 만니톨 180 mg, 인산일수소나트륨 25 mg, 주사용 물 2974 mgNovica vine extract 100 mg, mannitol 180 mg, sodium dihydrogen phosphate 25 mg, water for injection 2974 mg
제조예 4: 화장료의 제조Preparation Example 4 Preparation of Cosmetic
본 발명의 노박덩굴 추출물을 이용하여 다음과 같은 조성으로 에센스를 제조하였다.Essence was prepared by the following composition using the Novak vine extract of the present invention.
[조성][Furtherance]
노박덩굴 추출물 10.0 mg, 글리세린 3.0 mg, EDTA 0.05 mg, 벤조페논-9 0.04 mg, 카르복시비닐 폴리머 0.2 mg, 트리에탄올아민 0.18 mg, 옥시도테세스-25 0.6 mg, 글리세릴모노스테아레이트 1.0 mg, 방부제 0.01 mg, 향료 0.01 mg, 정제수 잔량Nova vine extract 10.0 mg, glycerin 3.0 mg, EDTA 0.05 mg, benzophenone-9 0.04 mg, carboxyvinyl polymer 0.2 mg, triethanolamine 0.18 mg, oxidodotheses-25 0.6 mg, glyceryl monostearate 1.0 mg, preservative 0.01 mg, fragrance 0.01 mg, remaining amount of purified water
제조예Production Example 5: 음료 제조 5: beverage manufacturing
본 발명의 노박덩굴 추출물 500 ㎎을 적당량의 물에 용해시킨 후에 보조성분으로서 비타민 C, 교미제로서 구연산, 구연산나트륨, 올리고당을 적당량 가하고, 보존제로서 적당량의 나트륨벤조에이트를 가한 후에 물을 가하여 전량을 100 ㎖로 만들어 음료용 조성물을 제조하였다. 이때 타우린이나 마이오 이노시톨, 엽산, 판토텐산 등을 단독으로 혹은 함께 첨가할 수 있다.After dissolving 500 mg of the Novak extract of the present invention in an appropriate amount of water, vitamin C as an auxiliary component, citric acid, sodium citrate, oligosaccharides as an auxiliary agent is added, and an appropriate amount of sodium benzoate is added as a preservative. 100 ml was prepared to prepare a beverage composition. At this time, taurine, myo-inositol, folic acid, pantothenic acid, etc. may be added alone or together.
이상에서 설명한 바와 같이, 본 발명은 노박덩굴(Celastrus orbiculatus) 추출물이 티로시네이즈 발현 억제활성, 멜라닌 생합성 저해 활성이 우수함을 확인함 으로써 노박덩굴 추출물을 유효성분으로 함유하는 피부 미백용 조성물에 관한 것으로서, 특히 노박덩굴 추출물이 천연에서 얻을 수 있기 때문에 안전하게 의약품, 화장품 또는 식품 등에 유용하게 사용될 수 있으리라 기대된다.As described above, the present invention relates to a composition for skin whitening containing Nova vine extract as an active ingredient by confirming that the extract of Nova celica ( Celastrus orbiculatus) is excellent in inhibiting tyrosinase expression and inhibiting melanin biosynthesis. In particular, it is expected that the Nova vine extract may be safely used in medicine, cosmetics or food because it is obtained from nature.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020060120894A KR100831092B1 (en) | 2006-12-01 | 2006-12-01 | Skin whitening composition containing celastrus orbiculatus extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020060120894A KR100831092B1 (en) | 2006-12-01 | 2006-12-01 | Skin whitening composition containing celastrus orbiculatus extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR100831092B1 true KR100831092B1 (en) | 2008-05-21 |
Family
ID=39664812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020060120894A KR100831092B1 (en) | 2006-12-01 | 2006-12-01 | Skin whitening composition containing celastrus orbiculatus extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100831092B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170017082A (en) | 2015-08-05 | 2017-02-15 | 대전대학교 산학협력단 | Composition for skin-whitener containing extract of china rose |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000060218A (en) * | 1999-03-12 | 2000-10-16 | 성재갑 | Oral compositions containing Celastrus Orbiculatus Thunb extracts |
-
2006
- 2006-12-01 KR KR1020060120894A patent/KR100831092B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000060218A (en) * | 1999-03-12 | 2000-10-16 | 성재갑 | Oral compositions containing Celastrus Orbiculatus Thunb extracts |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170017082A (en) | 2015-08-05 | 2017-02-15 | 대전대학교 산학협력단 | Composition for skin-whitener containing extract of china rose |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101088071B1 (en) | Novel use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same | |
| US20230075384A1 (en) | Composition containing plant extracts | |
| KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
| KR101671852B1 (en) | Skin whitening composition containing extract or fraction of Euphorbia maculata or Euphorbia supina | |
| KR20210108911A (en) | A composition for antioxidant or whitening compriging rosemary ionic liquid extract | |
| KR101295368B1 (en) | Composition for skin wrinkle improvement comprising extracts of honeybush extract or its fermentation solution as an active ingredient | |
| KR102299277B1 (en) | Composition for improving scalp condition comprising flower extract of passiflora edulis | |
| KR20160040969A (en) | Composition for preventing hair loss or accelerating hair growth comprising artemisia umbelliformis extract | |
| KR102114133B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
| KR102458480B1 (en) | A composition for stimulating growth of hairs contaning rhynchosia nulubilis complex extracts | |
| KR20100028202A (en) | Composition having skin whitening activity comprising an extract of buddleja officinalis | |
| KR100831092B1 (en) | Skin whitening composition containing celastrus orbiculatus extract | |
| KR102577528B1 (en) | Composition for improving skin | |
| KR102089209B1 (en) | Composition for skin whitening comprising guaiacol, phytol and cavacrol as active ingredients | |
| KR101579500B1 (en) | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen | |
| KR102201305B1 (en) | A composition for skin whitening comprising Cimicifuga dahurica extract or a fraction thereof | |
| KR102012366B1 (en) | Composition for whitening comprising Withania somnifera callus extract | |
| KR20170138307A (en) | Ultrasonic extract of Lespedeza cuneate and method for extracting the same | |
| KR101911003B1 (en) | Ultrasonic extract of Lespedeza cuneate and method for extracting the same | |
| KR20100092922A (en) | A skin whintening cosmetic composition containing a oriental herb extracts mixture stabilized by nanoliposome | |
| KR20150144688A (en) | Composition for improving scalp condition comprising extract of passiflora incarnate | |
| KR101526435B1 (en) | Compositions for skin-whitening comprising extract of Vitis amurensis ruprecht | |
| KR102249708B1 (en) | Composition for improving scalp condition comprising flower extract of passiflora quadrangularis | |
| KR102274305B1 (en) | Composition for improving scalp condition comprising flower extract of passiflora laurifolia | |
| KR102468186B1 (en) | Composition for Skin-lightening Using an Extract of Lotus corniculatus var. japonica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| N231 | Notification of change of applicant | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130515 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20140514 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20150514 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20160516 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20180515 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20190514 Year of fee payment: 12 |